Concert Pharmaceuticals commences Phase IIa trial to study CTP-543 in alopecia areata

US-based Concert Pharmaceuticals has commenced the Phase IIa clinical trial of CTP-543 to treat patients with moderate-to-severe alopecia areata.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news